Trial Profile
EVALUATION OF THE EFFICACY, SAFETY AND TOLERABILITY OF THE CONCURRENT ADMINISTRATION OF CHF 4226 HFA pMDI AND EXTRAFINE BUDESONIDE HFA pMDI, BOTH GIVEN ONCE OR TWICE DAILY (2microg + 200microg qd or 1microg + 100microg bid) OVER AN 8-WEEK RANDOMIZED DOUBLE-BLIND TREATMENT PERIOD IN ADULT PATIENTS WITH MODERATE PERSISTENT ASTHMA AND PRESENTING WITH SYMPTOMS ON EXISTING INHALED CORTICOSTEROID THERAPY.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jun 2011
Price :
$35
*
At a glance
- Drugs Budesonide/carmoterol (Primary) ; Budesonide; Carmoterol
- Indications Asthma
- Focus Therapeutic Use
- 03 Jun 2011 New trial record